Thermo Expanding Specialty Dx Business with $3.5 Billion Phadia Acquisition

The acquisition will significantly expand Thermo Fisher's specialty diagnostics business from current annual revenues of around $1.4 billion to roughly $1.9 billion.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.